Enzyme inhibitor discovery by activity-based protein profiling

Annual Review of Biochemistry

Volumn 83, Issue , 2014, Pages 341-377

  Niphakis, Micah J ^a   Cravatt, Benjamin F ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

activity based protein profiling; chemical proteomics; enzyme; inhibitor; target engagement

Indexed keywords

2 ARACHIDONOYLGLYCEROL; BORON DIPYRROMETHENE; CYSTEINE PROTEINASE; ENDOCANNABINOID; ENZYME; ENZYME INHIBITOR; ESTERASE INHIBITOR; FATTY ACID AMIDASE INHIBITOR; FLUORESCENT DYE; FLUOROPHOSPHONIC ACID DERIVATIVE; G PROTEIN COUPLED RECEPTOR; GLYCOSIDASE; HYDROLASE; JZL 184; KML 29; KT 109; KT 172; KT 195; METALLOHYDROLASE; PALMITOYL TRANSFERASE; PENICILLIN BINDING PROTEIN; PF 04457845; PHOSPHATASE; PROTEIN; PROTEIN KINASE; PROTEOME; SERINE HYDROLASE; TETRAHYDROCANNABINOL; TRANSFERASE; UNCLASSIFIED DRUG; UNINDEXED DRUG; LACTONE;

ACTIVITY BASED PROBE; ACTIVITY BASED PROTEIN PROFILING; ANTIPROLIFERATIVE ACTIVITY; CANCER CELL; CELL FUNCTION; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM; CLICK CHEMISTRY; CLOSTRIDIUM DIFFICILE; DRUG DESIGN; DRUG SCREENING; DRUG SYNTHESIS; ELECTROPHILICITY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME INHIBITOR INTERACTION; ENZYME SPECIFICITY; ENZYME SYNTHESIS; FLUORESCENCE MICROSCOPY; FLUOROSCOPY; HIGH THROUGHPUT SCREENING; HOST PATHOGEN INTERACTION; HUMAN; IN VIVO STUDY; MASS SPECTROMETRY; MOLECULAR BIOLOGY; MOLECULAR LIBRARY; MOLECULAR PROBE; NONHUMAN; PATHOGENESIS; PHENOTYPE; PHOTOCHEMISTRY; PLASMODIUM FALCIPARUM; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PROTEIN PROCESSING; PROTEIN TARGETING; PROTEOMICS; REVIEW; STRUCTURE ACTIVITY RELATION; SYSTEMS BIOLOGY; ANIMAL; BINDING COMPETITION; CHEMISTRY; DRUG DEVELOPMENT; GENE EXPRESSION PROFILING; MEDICINAL CHEMISTRY; PROCEDURES; TUMOR CELL LINE;

ANIMALS; BINDING, COMPETITIVE; CELL LINE, TUMOR; CHEMISTRY, PHARMACEUTICAL; DRUG DESIGN; DRUG DISCOVERY; ENZYME INHIBITORS; GENE EXPRESSION PROFILING; HUMANS; LACTONES; PHENOTYPE; PHOTOCHEMISTRY; PROTEOME; PROTEOMICS;

EID: 84902142324     PISSN: 00664154     EISSN: 15454509     Source Type: Book Series    
DOI: 10.1146/annurev-biochem-060713-035708     Document Type: Review

References (243)

1. Hill R, Needham J. 1970. The Chemistry of Life: Eight Lectures on the History of Biochemistry. Cambridge, UK: Cambridge Univ. Press. 213 pp.
2. Austin CP, Brady LS, Insel TR, Collins FS. 2004. NIHMolecular Libraries Initiative. Science 306:1138-39
3. Weiss WA, Taylor SS, Shokat KM. 2007. Recognizing and exploiting differences between RNAi and small-molecule inhibitors. Nat. Chem. Biol. 3:739-44
4. Knight ZA, Shokat KM. 2007. Chemical genetics: where genetics and pharmacology meet. Cell 128:425-30
5. Schirle M, Bantscheff M, Kuster B. 2012. Mass spectrometry-based proteomics in preclinical drug discovery. Chem. Biol. 19:72-84
6. Yates JR, Ruse CI, Nakorchevsky A. 2009. Proteomics by mass spectrometry: approaches, advances, and applications. Annu. Rev. Biomed. Eng. 11:49-79
7. Bensimon A, Heck AJR, Aebersold R. 2012. Mass spectrometry-based proteomics and network biology. Annu. Rev. Biochem. 81:379-405
8. Cox J, Mann M. 2011. Quantitative, high-resolution proteomics for data-driven systems biology. Annu. Rev. Biochem. 80:273-99
9. Wagner JA. 2008. Strategic approach to fit-for-purpose biomarkers in drug development. Annu. Rev. Pharmacol. Toxicol. 48:631-51
10. Li X, Gianoulis TA, Yip KY, Gerstein M, Snyder M. 2010. Extensive in vivo metabolite-protein interactions revealed by large-scale systematic analyses. Cell 143:639-50
11. Lee J, Bogyo M. 2013. Target deconvolution techniques in modern phenotypic profiling. Curr. Opin. Chem. Biol. 17:118-26
12. Sams-Dodd F. 2005. Target-based drug discovery: Is something wrong? Drug Discov. Today 10:139-47
13. Adibekian A, Martin BR,Wang C, Hsu KL, Bachovchin DA, et al. 2011. Click-generated triazole ureas as ultrapotent in vivo-Active serine hydrolase inhibitors. Nat. Chem. Biol. 7:469-78
14. Bachovchin DA, Ji T, Li W, Simon GM, Blankman JL, et al. 2010. Superfamily-wide portrait of serine hydrolase inhibition achieved by library-versus-library screening. Proc. Natl. Acad. Sci. USA 107:20941-46
15. Goldstein DM, Gray NS, Zarrinkar PP. 2008. High-throughput kinase profiling as a platform for drug discovery. Nat. Rev. Drug Discov. 7:391-97
16. ZhengW, Thorne N, McKew JC. 2013. Phenotypic screens as a renewed approach for drug discovery. Drug Discov. Today 18:1067-73
17. Burdine L, Kodadek T. 2004. Target identification in chemical genetics: the (often) missing link. Chem. Biol. 11:593-97
18. Leslie B, Hergenrother P. 2008. Identification of the cellular targets of bioactive small organicmolecules using affinity reagents. Chem. Soc. Rev. 37:1347-60
19. Ziegler S, Pries V, Hedberg C, Waldmann H. 2013. Target identification for small bioactive molecules: finding the needle in the haystack. Angew. Chem. Int. Ed. Engl. 52:2744-92
20. Raj L, Ide T, Gurkar AU, Foley M, Schenone M, et al. 2011. Selective killing of cancer cells by a small molecule targeting the stress response to ROS. Nature 475:231-34
21. Chen S, Do JT, Zhang Q, Yao S, Yan F, et al. 2006. Self-renewal of embryonic stem cells by a small molecule. Proc. Natl. Acad. Sci. USA 103:17266-71
22. Bradner JE, Mak R, Tanguturi SK, Mazitschek R, Haggarty SJ, et al. 2010. Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell disease. Proc. Natl. Acad. Sci. USA 107:12617-22
23. EvansMJ, Saghatelian A, Sorensen EJ, Cravatt BF. 2005. Target discovery in small-molecule cell-based screens by in situ proteome reactivity profiling. Nat. Biotechnol. 23:1303-7
24. Arastu-Kapur S, Ponder EL, Fonovìc UP, Yeoh S, Yuan F, et al. 2008. Identification of proteases that regulate erythrocyte rupture by the malaria parasite Plasmodium falciparum. Nat. Chem. Biol. 4:203-13
25. Hall CI,ReeseML, Weerapana E,Child MA, Bowyer PW, et al. 2011. Chemical genetic screen identifies Toxoplasma DJ-1 as a regulator of parasite secretion, attachment, and invasion. Proc. Natl. Acad. Sci. USA 108:10568-73
26. Tam Dang TH, de la Riva L, Fagan RP, Storck EM, Heal WP, et al. 2010. Chemical probes of surface layer biogenesis in Clostridium difficile. ACS Chem. Biol. 5:279-85
27. Washburn MP, Wolters D, Yates JR 3rd. 2001. Large-scale analysis of the yeast proteome by multidimensional protein identification technology. Nat. Biotechnol. 19:242-47
28. Gygi SP, Rist B, Gerber SA, Turecek F, GelbMH, Aebersold R. 1999. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat. Biotechnol. 17:994-99
29. Mann M. 2006. Functional and quantitative proteomics using SILAC. Nat. Rev. Mol. Cell Biol. 7:952-58
30. Petschnigg J, Snider J, Stagljar I. 2011. Interactive proteomics research technologies: recent applications and advances. Curr. Opin. Biotechnol. 22:50-58
31. Stormo GD, Zhao Y. 2010. Determining the specificity of protein-DNA interactions. Nat. Rev. Genet. 11:751-60
32. Witze ES, OldWM, Resing KA, Ahn NG. 2007. Mapping protein post-translational modifications with mass spectrometry. Nat. Methods 4:798-806
33. Zhao Y, Jensen ON. 2009. Modification-specific proteomics: strategies for characterization of posttranslational modifications using enrichment techniques. Proteomics 9:4632-41
34. HuhWK, Falvo JV, Gerke LC, Carroll AS, Howson RW, et al. 2003. Global analysis of protein localization in budding yeast. Nature 425:686-91
35. Kingsmore SF. 2006. Multiplexed protein measurement: technologies and applications of protein and antibody arrays. Nat. Rev. Drug Discov. 5:310-20
36. Lindsley JE, Rutter J. 2006. Whence cometh the allosterome? Proc. Natl. Acad. Sci. USA 103:10533-35
37. Kobe B, Kemp BE. 1999. Active site-directed protein regulation. Nature 402:373-76
38. Otlewski J, Jelen F, Zakrzewska M, Oleksy A. 2005. The many faces of protease-protein inhibitor interaction. EMBO J. 24:1303-10
39. Nomura DK, Long JZ, Niessen S, Hoover HS, Ng SW, Cravatt BF. 2010. Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis. Cell 140:49-61
40. Jessani N, Humphrey M, McDonald WH, Niessen S, Masuda K, et al. 2004. Carcinoma and stromal enzyme activity profiles associated with breast tumor growth in vivo. Proc.Natl. Acad. Sci.USA101:13756-61
41. Heal WP, Tate EW. 2012. Application of activity-based protein profiling to the study of microbial pathogenesis. Top. Curr. Chem. 324:115-35
42. Leung D, Hardouin C, Boger DL, Cravatt BF. 2003. Discovering potent and selective reversible inhibitors of enzymes in complex proteomes. Nat. Biotechnol. 21:687-91
43. Li W, Blankman JL, Cravatt BF. 2007. A functional proteomic strategy to discover inhibitors for uncharacterized hydrolases. J. Am. Chem. Soc. 129:9594-95
44. Adam GC, Burbaum J, Kozarich JW, Patricelli MP, Cravatt BF. 2004. Mapping enzyme active sites in complex proteomes. J. Am. Chem. Soc. 126:1363-68
45. Zeiler E, List A, Alte F, Gersch M, Wachtel R, et al. 2013. Structural and functional insights into caseinolytic proteases reveal an unprecedented regulation principle of their catalytic triad. Proc. Natl. Acad. Sci. USA 110:11302-7
46. Bachovchin DA, Brown SJ, Rosen H, Cravatt BF. 2009. Identification of selective inhibitors of uncharacterized enzymes by high-throughput screening with fluorescent activity-based probes. Nat. Biotechnol. 27:387-94
47. Chang JW,Moellering RE,Cravatt BF. 2012. An activity-based imaging probe for the integral membrane hydrolase KIAA1363. Angew. Chem. Int. Ed. Engl. 51:966-70
48. Edgington LE, Berger AB, Blum G, Albrow VE, Paulick MG, et al. 2009. Noninvasive optical imaging of apoptosis by caspase-targeted activity-based probes. Nat. Med. 15:967-73
49. Williams SJ, Hekmat O, Withers SG. 2006. Synthesis and testing of mechanism-based protein-profiling probes for retaining endo-glycosidases. ChemBioChem 7:116-24
50. Vocadlo DJ, Bertozzi CR. 2004. A strategy for functional proteomic analysis of glycosidase activity from cell lysates. Angew. Chem. Int. Ed. Engl. 43:5338-42
51. Stubbs K, Scaffidi A, Debowski AW, Mark BL, Stick RV, Vocadlo DJ. 2008. Synthesis and use of mechanism-based protein-profiling probes for retaining β-D-glucosaminidases facilitate identification of Pseudomonas aeruginosa NagZ. J. Am. Chem. Soc. 130:327-35
52. Chauvigǹe-Hines LM, Anderson LN,Weaver HM, Brown JN, Koech PK, et al. 2012. Suite of activitybased probes for cellulose-degrading enzymes. J. Am. Chem. Soc. 134:20521-32
53. Kato D, Boatright KM, Berger AB, Nazif T, Blum G, et al. 2005. Activity-based probes that target diverse cysteine protease families. Nat. Chem. Biol. 1:33-38
54. Tsuboi K, Bachovchin DA, Speers AE, Spicer TP, Fernandez-Vega V, et al. 2011. Potent and selective inhibitors of glutathione S-transferase ω1 that impair cancer drug resistance. J. Am. Chem. Soc. 133:16605-16
55. Greenbaum DC, Arnold WD, Lu F, Hayrapetian L, Baruch A, et al. 2002. Small molecule affinity fingerprinting. A tool for enzyme family subclassification, target identification, and inhibitor design. Chem. Biol. 9:1085-94
56. Patricelli MP, Szardenings AK, Liyanage M, Nomanbhoy TK, Wu M, et al. 2007. Functional interrogation of the kinome using nucleotide acyl phosphates. Biochemistry 46:350-58
57. Tsai C-S, Yen H-Y, Lin M-I, Tsai T-I, Wang S-Y, et al. 2013. Cell-permeable probe for identification and imaging of sialidases. Proc. Natl. Acad. Sci. USA 110:2466-71
58. Liu Y, Patricelli MP, Cravatt BF. 1999. Activity-based protein profiling: the serine hydrolases. Proc. Natl. Acad. Sci. USA 96:14694-99
59. Patricelli MP,GiangDK, StampLM, Burbaum JJ. 2001. Direct visualization of serine hydrolase activities in complex proteomes using fluorescent active site-directed probes. Proteomics 1:1067-71
60. Blair JA, Rauh D, Kung C, Yun C-H, Fan Q-W, et al. 2007. Structure-guided development of affinity probes for tyrosine kinases using chemical genetics. Nat. Chem. Biol. 3:229-38
61. Heal WP, Dang TH, Tate EW. 2011. Activity-based probes: discovering new biology and new drug targets. Chem. Soc. Rev. 40:246-57
62. Saghatelian A, Jessani N, Joseph A, Humphrey M, Cravatt BF. 2004. Activity-based probes for the proteomic profiling of metalloproteases. Proc. Natl. Acad. Sci. USA 101:10000-5
63. Salisbury CM, Cravatt BF. 2007. Activity-based probes for proteomic profiling of histone deacetylase complexes. Proc. Natl. Acad. Sci. USA 104:1171-76
64. Sieber SA, Niessen S, Hoover HS, Cravatt BF. 2006. Proteomic profiling of metalloprotease activities with cocktails of active-site probes. Nat. Chem. Biol. 2:274-81
65. SalisburyCM, Cravatt BF. 2008. Optimization of activity-based probes for proteomic profiling of histone deacetylase complexes. J. Am. Chem. Soc. 130:2184-94
66. Ranjitkar P, Perera B, Swaney D, Swaney DL, Hari S, et al. 2012. Affinity-based probes based on type II kinase inhibitors. J. Am. Chem. Soc. 134:19017-25
67. Shi H, Zhang C-J, Chen GY, Yao SQ. 2012. Cell-based proteome profiling of potential dasatinib targets by use of affinity-based probes. J. Am. Chem. Soc. 134:3001-14
68. Li Z, Hao P, Li L, Tan CYJ, Cheng X, et al. 2013. Design and synthesis of minimalist terminal alkynecontaining diazirine photo-crosslinkers and their incorporation into kinase inhibitors for cell-and tissuebased proteome profiling. Angew. Chem. Int. Ed. Engl. 52:8551-56
69. Cisar JS, Cravatt BF. 2012. Fully functionalized small-molecule probes for integrated phenotypic screening and target identification. J. Am. Chem. Soc. 134:10385-88
70. George Cisar EA, Nguyen N, Rosen H. 2013. A GTP affinity probe for proteomics highlights flexibility in purine nucleotide selectivity. J. Am. Chem. Soc. 135:4676-79
71. Hulce JJ, Cognetta AB, Niphakis MJ, Tully SE, Cravatt BF. 2013. Proteome-wide mapping of cholesterol-interacting proteins in mammalian cells. Nat. Methods 10:259-64
72. Kidd D, Liu Y, Cravatt BF. 2001. Profiling serine hydrolase activities in complex proteomes. Biochemistry 40:4005-15
73. Kumar S, Zhou B, Liang F,WangW-Q, Huang Z, Zhang Z-Y. 2004. Activity-based probes for protein tyrosine phosphatases. Proc. Natl. Acad. Sci. USA 101:7943-48
74. Patricelli MP, Nomanbhoy TK, Wu J, Brown H, Zhou D, et al. 2011. In situ kinase profiling reveals functionally relevant properties of native kinases. Chem. Biol. 18:699-710
75. Borodovsky A, Kessler BM, Casagrande R, Overkleeft HS, Wilkinson KD, Ploegh HL. 2001. A novel active site-directed probe specific for deubiquitylating enzymes reveals proteasome association ofUSP14. EMBO J. 20:5187-96
76. Altun M, Kramer HB, Willems LI, McDermott JL, Leach CA, et al. 2011. Activity-based chemical proteomics accelerates inhibitor development for deubiquitylating enzymes. Chem. Biol. 18:1401-12
77. Borodovsky A,OvaaH, Kolli N, Gan-Erdene T, Wilkinson KD, et al. 2002. Chemistry-based functional proteomics reveals novel members of the deubiquitinating enzyme family. Chem. Biol. 9:1149-59
78. Wright AT, Song JD, Cravatt BF. 2009. A suite of activity-based probes for human cytochrome P450 enzymes. J. Am. Chem. Soc. 131:10692-700
79. Krysiak JM,Kreuzer J, Macheroux P, Hermetter A, Sieber SA, Breinbauer R. 2012. Activity-based probes for studying the activity of flavin-dependent oxidases and for the protein target profiling of monoamine oxidase inhibitors. Angew. Chem. Int. Ed. Engl. 51:7035-40
80. Rotili D, Altun M, Kawamura A,Wolf A, Fischer R, et al. 2011. A photoreactive small-molecule probe for 2-oxoglutarate oxygenases. Chem. Biol. 18:642-54
81. Böttcher T, Sieber S. 2008. β-Lactones as privileged structures for the active-site labeling of versatile bacterial enzyme classes. Angew. Chem. Int. Ed. Engl. 47:4600-3
82. Adam GC, Sorensen E, Cravatt BF. 2002. Proteomic profiling ofmechanistically distinct enzyme classes using a common chemotype. Nat. Biotechnol. 20:805-9
83. Speers AE, Adam GC, Cravatt BF. 2003. Activity-based protein profiling in vivo using a copper(I)-catalyzed azide-Alkyne [3 + 2] cycloaddition. J. Am. Chem. Soc. 125:4686-87
84. Speers AE, Cravatt BF. 2004. Profiling enzyme activities in vivo using click chemistry methods. Chem. Biol. 11:535-46
85. Adibekian A, Martin BR, Chang JW, Hsu KL, Tsuboi K, et al. 2012. Confirming target engagement for reversible inhibitors in vivo by kinetically tuned activity-based probes. J. Am. Chem. Soc. 134:10345-48
86. Chang JW, Cognetta AB , Niphakis MJ, Cravatt BF. 2013. Proteome-wide reactivity profiling identifies diverse carbamate chemotypes tuned for serine hydrolase inhibition. ACS Chem. Biol. 8:1590-99
87. Ahn K, Johnson DS, Mileni M, Beidler D, Long JZ, et al. 2009. Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain. Chem. Biol. 16:411-20
88. Rostovtsev VV, Green LG, Fokin VV, Sharpless BK. 2002. A stepwise Huisgen cycloaddition process: copper(I)-catalyzed regioselective "ligation" of azides and terminal alkynes. Angew. Chem. Int. Ed. Engl. 41:2596-99
89. Blum G, Mullins SR, Keren K, FonovìcM, Jedeszko C, et al. 2005. Dynamic imaging of protease activity with fluorescently quenched activity-based probes. Nat. Chem. Biol. 1:203-9
90. Joyce JA, Baruch A, Chehade K, Meyer-Morse N, Giraudo E, et al. 2004. Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. Cancer Cell 5:443-53
91. Edgington LE, Verdoes M, Bogyo M. 2011. Functional imaging of proteases: recent advances in the design and application of substrate-based and activity-based probes. Curr. Opin. Chem. Biol. 15:798-805
92. Blum G, von Degenfeld G, Merchant MJ, Blau HM, Bogyo M. 2007. Noninvasive optical imaging of cysteine protease activity using fluorescently quenched activity-based probes. Nat. Chem. Biol. 3:668-77
93. Blum G, Weimer RM, Edgington LE, AdamsW, BogyoM. 2009. Comparative assessment of substrates and activity based probes as tools for non-invasive optical imaging of cysteine protease activity. PLoS ONE 4:e6374
94. Lee J, BogyoM. 2010. Development of near-infrared fluorophore (NIRF)-labeled activity-based probes for in vivo imaging of legumain. ACS Chem. Biol. 5:233-43
95. Verdoes M, Oresic Bender K, Segal E, van der Linden WA, Syed S, et al. 2013. Improved quenched fluorescent probe for imaging of cysteine cathepsin activity. J. Am. Chem. Soc. 135:14726-30
96. Verdoes M, Florea BI, Menendez-Benito V, Maynard CJ,Witte MD, et al. 2006. A fluorescent broadspectrum proteasome inhibitor for labeling proteasomes in vitro and in vivo. Chem. Biol. 13:1217-26
97. Kocaoglu O, Calvo RA, Sham LT, Cozy LM, Lanning BR, et al. 2012. Selective penicillin-binding protein imaging probes reveal substructure in bacterial cell division. ACS Chem. Biol. 7:1746-53
98. Matthews PM, Rabiner EA, Passchier J, Gunn RN. 2012. Positron emission tomography molecular imaging for drug development. Br. J. Clin. Pharmacol. 73:175-86
99. SkaddanMB, ZhangLS, Johnson D, Zhu A,Zasadny KR, et al. 2012. The synthesis and in vivo evaluation of [18F]PF-9811: a novel PET ligand for imaging brain fatty acid amide hydrolase (FAAH). Nucl. Med. Biol. 39:1058-67
100. Wilson AA, Garcia A, Parkes J, Houle S, Tong J, Vasdev N. 2011. [11C]CURB: evaluation of a novel radiotracer for imaging fatty acid amide hydrolase by positron emission tomography. Nucl. Med. Biol. 38:247-53
101. Ren G, Blum G, Verdoes M, Liu H, Syed S, et al. 2011. Non-invasive imaging of cysteine cathepsin activity in solid tumors using a 64Cu-labeled activity-based probe. PLoS ONE 6:e28029
102. Moellering RE, Cravatt BF. 2012. How chemoproteomics can enable drug discovery and development. Chem. Biol. 19:11-22
103. Berkers CR, Verdoes M, Lichtman E, Fiebiger E, Kessler BM, et al. 2005. Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib. Nat. Methods 2:357-62
104. Bachovchin DA, Mohr JT, Speers AE, Wang C, Berlin JM, et al. 2011. Academic cross-fertilization by public screening yields a remarkable class of protein phosphatase methylesterase-1 inhibitors. Proc. Natl. Acad. Sci. USA 108:6811-16
105. Long JZ, Nomura DK, Cravatt BF. 2009. Characterization ofmonoacylglycerol lipase inhibition reveals differences in central and peripheral endocannabinoid metabolism. Chem. Biol. 16:744-53
106. Ong S-E. 2012. The expanding field of SILAC. Anal. Bioanal. Chem. 404:967-76
107. Evans C, Noirel J, Ow SY, Salim M, Pereira-Medrano AG, et al. 2012. An insight into iTRAQ:Where do we stand now? Anal. Bioanal. Chem. 404:1011-27
108. Wolf EV, Zeibler A, Vosyka O, Zeiler E, Sieber S,Verhelst SHL. 2013. A new class of rhomboid protease inhibitors discovered by activity-based fluorescence polarization. PLoS ONE 8:e72307
109. Lone AM, Bachovchin DA, Westwood DB, Speers AE, Spicer TP, et al. 2011. A substrate-free activitybased protein profiling screen for the discovery of selective PREPL inhibitors. J. Am. Chem. Soc. 133:11665-74
110. Dillon MB, Bachovchin DA, Brown SJ, Finn MG, Rosen H, et al. 2012. Novel inhibitors for PRMT1 discovered by high-throughput screening using activity-based fluorescence polarization. ACS Chem. Biol. 7:1198-204
111. Knuckley B, Jones JE, Bachovchin DA, Slack J, Causey CP, et al. 2010. A fluopol-ABPP HTS assay to identify PAD inhibitors. Chem. Commun. 46:7175-77
112. Long JZ, CravattBF. 2011.Themetabolic serine hydrolases and their functions inmammalian physiology and disease. Chem. Rev. 111:6022-63
113. Bachovchin DA, Cravatt BF. 2012. The pharmacological landscape and therapeutic potential of serine hydrolases. Nat. Rev. Drug Discov. 11:52-68
114. 2. Nature 390:622-25
115. Nomura DK,Morrison BE, Blankman JL, Long JZ, Kinsey SG, et al. 2011. Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation. Science 334:809-13
116. Lane RM, Potkin SG, Enz A. 2006. Targeting acetylcholinesterase and butyrylcholinesterase in dementia. Int. J. Neuropsychopharmacol. 9:101-24
117. Merkel M, Eckel RH, Goldberg IJ. 2002. Lipoprotein lipase: genetics, lipid uptake, and regulation. J. Lipid Res. 43:1997-2006
118. Davie EW, Ratnoff OD. 1964. Waterfall sequence for intrinsic blood clotting. Science 145:1310-12
119. White MJ, Savaryn JP, Bretl DJ, He H, Penoske RM, et al. 2011. The HtrA-like serine protease PepD interacts with and modulates the Mycobacterium tuberculosis 35-kDa antigen outer envelope protein. PLoS ONE 6:e18175
120. Dodson G, Wlodawer A. 1998. Catalytic triads and their relatives. Trends Biochem. Sci. 23:347-52
121. Kraut J. 1977. Serine proteases: structure and mechanism of catalysis. Annu. Rev. Biochem. 46:331-58
122. Simon GM, Cravatt BF. 2010. Activity-based proteomics of enzyme superfamilies: serine hydrolases as a case study. J. Biol. Chem. 285:11051-55
123. Nomura DK, Dix MM, Cravatt BF. 2010. Activity-based protein profiling for biochemical pathway discovery in cancer. Nat. Rev. Cancer 10:630-38
124. Blankman JL, Cravatt BF. 2013. Chemical probes of endocannabinoid metabolism. Pharmacol. Rev. 65:849-71
125. Cravatt BF, Demarest K, Patricelli MP, Bracey MH, Giang DK, et al. 2001. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling inmice lacking fatty acid amide hydrolase. Proc. Natl. Acad. Sci. USA 98:9371-76
126. Kathuria S, Gaetani S, Fegley D, Valino F, Duranti A, et al. 2003. Modulation of anxiety through blockade of anandamide hydrolysis. Nat. Med. 9:76-81
127. Li GL,WinterH, Arends R, Jay GW, Le V, et al. 2012. Assessment of the pharmacology and tolerability of PF-04457845, an irreversible inhibitor of fatty acid amide hydrolase-1, in healthy subjects. Br. J. Clin. Pharmacol. 73:706-16
128. Ahn K, Smith SE, Liimatta MB, Beidler D, Sadagopan N, et al. 2011. Mechanistic and pharmacological characterization of PF-04457845: a highly potent and selective fatty acid amide hydrolase inhibitor that reduces inflammatory and noninflammatory pain. J. Pharmacol. Exp. Ther. 338:114-24
129. Otrubova K, Ezzili C, Boger DL. 2011. The discovery and development of inhibitors of fatty acid amide hydrolase (FAAH). Bioorg. Med. Chem. Lett. 21:4674-85
130. King AR, Duranti A, Tontini A, Rivara S, Rosengarth A, et al. 2007. URB602 inhibits monoacylglycerol lipase and selectively blocks 2-Arachidonoylglycerol degradation in intact brain slices. Chem. Biol. 14:1357-65
131. Saario SM, Salo OM,Nevalainen T, Poso A, Laitinen JT, et al. 2005. Characterization of the sulfhydrylsensitive site in the enzyme responsible for hydrolysis of 2-Arachidonoyl-glycerol in rat cerebellar membranes. Chem. Biol. 12:649-56
132. Hohmann AG, Suplita RL, Bolton NM, Neely MH, Fegley D, et al. 2005. An endocannabinoid mechanism for stress-induced analgesia. Nature 435:1108-12
133. Vandevoorde S, Jonsson KO, Labar G, Persson E, Lambert DM, Fowler CJ. 2007. Lack of selectivity of URB602 for 2-oleoylglycerol compared to anandamide hydrolysis in vitro. Br. J. Clin. Pharmacol. 150:186-91
134. Blankman JL, Simon GM, Cravatt BF. 2007. A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-Arachidonoylglycerol. Chem. Biol. 14:1347-56
135. Chang JW, Niphakis MJ, Lum KM, Cognetta AB III, Wang C, et al. 2012. Highly selective inhibitors of monoacylglycerol lipase bearing a reactive group that is bioisosteric with endocannabinoid substrates. Chem. Biol. 19:579-88
136. Niphakis MJ, Cognetta AB III, Chang JW, Buczynski MW, Parsons LH, et al. 2013. Evaluation of NHS carbamates as a potent and selective class of endocannabinoid hydrolase inhibitors. ACS Chem. Neurosci. 4:1322-32
137. Aaltonen N, Savinainen JR, Ribas CR, Rönkkö J, Kuusisto A, et al. 2013. Piperazine and piperidine triazole ureas as ultrapotent and highly selective inhibitors of monoacylglycerol lipase. Chem. Biol. 20:379-90
138. Kinsey SG, Long JZ, Cravatt BF, Lichtman AH. 2010. Fatty acid amide hydrolase and monoacylglycerol lipase inhibitors produce anti-Allodynic effects in mice through distinct cannabinoid receptor mechanisms. J. Pain 11:1420-28
139. Khasabova IA, Chandiramani A, Harding-Rose C, Simone DA, Seybold VS. 2011. Increasing 2-arachidonoyl glycerol signaling in the periphery attenuates mechanical hyperalgesia in a model of bone cancer pain. Pharmacol. Res. 64:60-67
140. Ignatowska-Jankowska BM, Ghosh S, Crowe MS, Kinsey SG, Niphakis MJ, et al. 2014. In vivo characterization of the highly selective monoacylglycerol lipase inhibitor KML29: antinociceptive activity without cannabimimetic side effects. Br. J. Pharmacol. 171:1392-407
141. Busquets-Garcia A, Puighermanal E, Pastor A, de la Torre R, Maldonado R,Ozaita A. 2011. Differential role of anandamide and 2-Arachidonoylglycerol in memory and anxiety-like responses. Biol. Psychiatry 70:479-86
142. Kinsey SG,ONeal S, Long JZ, CravattBF, Lichtman AH. 2011. Inhibition of endocannabinoid catabolic enzymes elicits anxiolytic-like effects in the marble burying assay. Pharmacol. Biochem. Behav. 98:21-27
143. Schlosburg JE, Blankman JL, Long JZ, Nomura DK, Pan B, et al. 2010. Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system. Nat. Neurosci. 13:1113-19
144. Chanda PK,Gao Y, Mark L, Btesh J, Strassle BW, et al. 2010. Monoacylglycerol lipase activity is a critical modulator of the tone and integrity of the endocannabinoid system. Mol. Pharmacol. 78:996-1003
145. Taschler U, Radner FP,Heier C, Schreiber R, Schweiger M, et al. 2011. Monoglyceride lipase deficiency in mice impairs lipolysis and attenuates diet-induced insulin resistance. J. Biol. Chem. 286:17467-77
146. Lanoir J, Hilaire G, Seif I. 2006. Reduced density of functional 5-HT1A receptors in the brain, medulla and spinal cord of monoamine oxidase A knockout mouse neonates. J. Comp. Neurol. 495:607-23
147. Kinsey SG, Wise LE, Ramesh D, Abdullah R, Selley DE, et al. 2013. Repeated low-dose administration of the monoacylglycerol lipase inhibitor JZL184 retains cannabinoid receptor type 1-mediated antinociceptive and gastroprotective effects. J. Pharmacol. Exp. Ther. 345:492-501
148. Bisogno T, Howell F, Williams G, Minassi A, Cascio MG, et al. 2003. Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. J. Cell Biol. 163:463-68
149. Gao Y, Vasilyev DV, Goncalves MB, Howell FV, Hobbs C, et al. 2010. Loss of retrograde endocannabinoid signaling and reduced adult neurogenesis in diacylglycerol lipase knock-out mice. J. Neurosci. 30:2017-24
150. Hoover HS, Blankman JL, Niessen S, Cravatt BF. 2008. Selectivity of inhibitors of endocannabinoid biosynthesis evaluated by activity-based protein profiling. Bioorg. Med. Chem. Lett. 18:5838-41
151. Piro JR, Benjamin DI, Duerr JM, Pi Y, Gonzales C, et al. 2012. A dysregulated endocannabinoideicosanoid network supports pathogenesis in a mouse model of Alzheimers disease. Cell Rep. 1:617-23
152. Hermanson DJ, Hartley ND, Gamble-George J, Brown N, Shonesy BC, et al. 2013. Substrate-selective COX-2 inhibition decreases anxiety via endocannabinoid activation. Nat. Neurosci. 16:1291-98
153. Berger AB, Witte MD, Denault J-B, Sadaghiani AM, Sexton KM, et al. 2006. Identification of early intermediates of caspase activation using selective inhibitors and activity-based probes. Mol. Cell 23:509-21
154. Greenbaum DC, Baruch A, Grainger M, Bozdech Z, Medzihradszky KF, et al. 2002. A role for the protease falcipain 1 in host cell invasion by the human malaria parasite. Science 298:2002-6
155. Verdoes M, Edgington LE, Scheeren FA, Leyva M, Blum G, et al. 2012. A nonpeptidic cathepsin S activity-based probe for noninvasive optical imaging of tumor-Associated macrophages. Chem. Biol. 19:619-28
156. Hang HC, Loureiro J, Spooner E, van der Velden AW, Kim Y-M, et al. 2006. Mechanism-based probe for the analysis of cathepsin cysteine proteases in living cells. ACS Chem. Biol. 1:713-23
157. Paulick MG, Bogyo M. 2011. Development of activity-based probes for cathepsin X. ACS Chem. Biol. 6:563-72
158. Watzke A, Kosec G, Kindermann M, Jeske V, Nestler H-P, et al. 2008. Selective activity-based probes for cysteine cathepsins. Angew. Chem. Int. Ed. Engl. 47:406-9
159. Edgington LE, Verdoes M, Ortega A,Withana NP, Lee J, et al. 2013. Functional imaging of legumain in cancer using a new quenched activity-based probe. J. Am. Chem. Soc. 135:174-82
160. Rosenthal PJ. 2011. Falcipains and other cysteine proteases of malaria parasites. Adv. Exp. Med. Biol. 712:30-48
161. Pink R, Hudson A, Mouriés M-A, Bendig M. 2005. Opportunities and challenges in antiparasitic drug discovery. Nat. Rev. Drug Discov. 4:727-40
162. Klemba M, Goldberg DE. 2002. Biological roles of proteases in parasitic protozoa. Annu. Rev. Biochem. 71:275-305
163. Greenbaum D, Medzihradszky KF, Burlingame A, Bogyo M. 2000. Epoxide electrophiles as activitydependent cysteine protease profiling and discovery tools. Chem. Biol. 7:569-81
164. Zhang J, Yang PL, Gray NS. 2009. Targeting cancer with small molecule kinase inhibitors. Nat. Rev. Cancer 9:28-39
165. Mary JS, Diane EG. 2009. Advances in the development of kinase inhibitor therapeutics for Alzheimer's disease. Drug Dev. Res. 70:125-44
166. Davis M, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, et al. 2011. Comprehensive analysis of kinase inhibitor selectivity. Nat. Biotechnol. 29:1046-51
167. Fabian MA, Biggs WH III, Treiber DK, Atteridge CE, Azimioara MD, et al. 2005. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat. Biotechnol. 23:329-36
168. Bantscheff M, Eberhard D, Abraham Y, Bastuck S, Boesche M, et al. 2007. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat. Biotechnol. 25:1035-44
169. Ong S-E, Schenone M, Margolin AA, Li X, Do K, et al. 2009. Identifying the proteins to which smallmolecule probes and drugs bind in cells. Proc. Natl. Acad. Sci. USA 106:4617-22
170. Degterev A, Hitomi J, Germscheid M, Ch'en IL, Korkina O, et al. 2008. Identification of RIP1 kinase as a specific cellular target of necrostatins. Nat. Chem. Biol. 4:313-21
171. Yang Q, Deng X, Lu B, Cameron M, Fearns C, et al. 2010. Pharmacological inhibition of BMK1 suppresses tumor growth through promyelocytic leukemia protein. Cancer Cell 18:258-67
172. Deng X, Dzamko N, Prescott A, Davies P, Liu Q, et al. 2011. Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2. Nat. Chem. Biol. 7:203-5
173. Liu Q, Sabnis Y, Zhao Z, Zhang T, Buhrlage SJ, et al. 2013. Developing irreversible inhibitors of the protein kinase cysteinome. Chem. Biol. 20:146-59
174. Barf T, Kaptein A. 2012. Irreversible protein kinase inhibitors: balancing the benefits and risks. J. Med. Chem. 55:6243-62
175. Singh J, Petter RC, Baillie TA,Whitty A. 2011. The resurgence of covalent drugs. Nat. Rev. Drug Discov. 10:307-17
176. Anjum R, Blenis J. 2008. The RSK family of kinases: emerging roles in cellular signalling. Nat. Rev. Mol. Cell Biol. 9:747-58
177. Cohen MS, Hadjivassiliou H, Taunton J. 2007. A clickable inhibitor reveals context-dependent autoactivation of p90 RSK. Nat. Chem. Biol. 3:156-60
178. CohenMS, Zhang C, Shokat KM, Taunton J. 2005. Structural bioinformatics-based design of selective, irreversible kinase inhibitors. Science 308:1318-21
179. Doehn U, Hauge C, Frank SR, Jensen CJ, Duda K, et al. 2009. RSK is a principal effector of the RAS-ERK pathway for eliciting a coordinate promotile/invasive gene program and phenotype in epithelial cells. Mol. Cell 35:511-22
180. Jin L, Li D, Lee JS, Elf S, Alesi GN, et al. 2013. p90 RSK2 mediates antianoikis signals by both transcription-dependent and -independent mechanisms. Mol. Cell. Biol. 33:2574-85
181. + exchanger isoform 1. J. Neurochem. 114:1476-86
182. Hetzer C, Bisgrove D, CohenMS, Pedal A, Kaehlcke K, et al. 2007. Recruitment and activation of RSK2 by HIV-1 Tat. PLoS ONE 2:e151
183. Kang S,Dong S,GuTL,Guo A, CohenMS, et al. 2007.FGFR3activatesRSK2to mediate hematopoietic transformation through tyrosine phosphorylation of RSK2 and activation of the MEK/ERK pathway. Cancer Cell 12:201-14
184. Leung D, Hardouin C, Boger DL, Cravatt BF. 2003. Discovering potent and selective reversible inhibitors of enzymes in complex proteomes. Nat. Biotechnol. 21:687-91
185. Jessani N, Liu Y,HumphreyM,Cravatt BF. 2002. Enzyme activity profiles of the secreted and membrane proteome that depict cancer cell invasiveness. Proc. Natl. Acad. Sci. USA 99:10335-40
186. Jessani N, Niessen S, Wei BQ, Nicolau M, Humphrey M, et al. 2005. A
187. Chiang KP, Niessen S, Saghatelian A, Cravatt BF. 2006. An enzyme that regulates ether lipid signaling pathways in cancer annotated by multidimensional profiling. Chem. Biol. 13:1041-50
188. BlankML, Smith ZL, Cress EA, Snyder F. 1990. Characterization of the enzymatic hydrolysis of acetate from alkylacetylglycerols in the de novo pathway of PAF biosynthesis. Biochim. Biophys. Acta 1042:153-58
189. Roos DS, Choppin PW. 1984. Tumorigenicity of cell lines with altered lipid composition. Proc. Natl. Acad. Sci. USA 81:7622-26
190. Chang JW, Nomura DK, Cravatt BF. 2011. A potent and selective inhibitor of KIAA1363/AADACL1 that impairs prostate cancer pathogenesis. Chem. Biol. 18:476-84
191. Holly SP, Chang JW, Li W, Niessen S, Phillips RM, et al. 2013. Chemoproteomic discovery of AADACL1 as a regulator of human platelet activation. Chem. Biol. 20:1125-34
192. Niphakis MJ, Johnson DS, Ballard TE, Stiff C, Cravatt BF. 2012. O-Hydroxyacetamide carbamates as a highly potent and selective class of endocannabinoid hydrolase inhibitors. ACS Chem. Neurosci. 3:418-26
193. Dhillon S. 2011. Rivastigmine transdermal patch: a review of its use in the management of dementia of the Alzheimer's type. Drugs 71:1209-31
194. Long JZ, Li W, Booker L, Burston JJ, Kinsey SG, et al. 2009. Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. Nat. Chem. Biol. 5:37-44
195. Marrs WR, Blankman JL, Horne EA, Thomazeau A, Lin YH, et al. 2010. The serine hydrolase ABHD6 controls the accumulation and efficacy of 2-AG at cannabinoid receptors. Nat. Neurosci. 13:951-57
196. Tchantchou F, Zhang Y. 2013. Selective inhibition of ?/β-hydrolase domain 6 attenuates neurodegeneration, alleviates blood brain barrier breakdown, and improves functional recovery in a mouse model of traumatic brain injury. J. Neurotraum. 30:565-79
197. Zuhl AM, Mohr JT, Bachovchin DA, Niessen S,Hsu K-L, et al. 2012. Competitive activity-based protein profiling identifies aza-β-lactams as a versatile chemotype for serine hydrolase inhibition. J. Am. Chem. Soc. 134:5068-71
198. Hsu K-L, Tsuboi K, Adibekian A, Pugh H, Masuda K, Cravatt BF. 2012. DAGLβinhibition perturbs a lipid network involved in macrophage inflammatory responses. Nat. Chem. Biol. 8:999-1007
199. Gersch M, Kreuzer J, Sieber SA. 2012. Electrophilic natural products and their biological targets. Nat. Prod. Rep. 29:659-82
200. Drahl C, Cravatt BF, Sorensen EJ. 2005. Protein-reactive natural products. Angew. Chem. Int. Ed. Engl. 44:5788-809
201. Böttcher T, Sieber SA. 2012. β-Lactams and β-lactones as activity-based probes in chemical biology. MedChemComm 3:408-17
202. Nelson RH, Miles JM. 2005. The use of orlistat in the treatment of obesity, dyslipidaemia and type 2 diabetes. Expert Opin. Pharmacother. 6:2483-91
203. Hadváry P, Sidler W, Meister W, Vetter W, Wolfer H. 1991. The lipase inhibitor tetrahydrolipstatin binds covalently to the putative active site serine of pancreatic lipase. J. Biol. Chem. 266:2021-27
204. Yang P-Y, Liu K, Ngai MH, Lear MJ,Wenk MR, Yao SQ. 2010. Activity-based proteome profiling of potential cellular targets of orlistat-An FDA-Approved drug with anti-tumor activities. J. Am. Chem. Soc. 132:656-66
205. Ngai MH, Yang P-Y, Liu K, Shen Y, Wenk MR, et al. 2010. Click-based synthesis and proteomic profiling of lipstatin analogues. Chem. Commun. 46:8335-37
206. Böttcher T, Sieber SA. 2008. β-Lactones as privileged structures for the active-site labeling of versatile bacterial enzyme classes. Angew. Chem. Int. Ed. Engl. 47:4600-3
207. Böttcher T, Sieber SA. 2008. β-Lactones as specific inhibitors of ClpP attenuate the production of extracellular virulence factors of Staphylococcus aureus. J. Am. Chem. Soc. 130:14400-1
208. Frees D, Qazi SN, Hill PJ, Ingmer H. 2003. Alternative roles of ClpX and ClpP in Staphylococcus aureus stress tolerance and virulence. Mol. Microbiol. 48:1565-78
209. Böttcher T, Sieber SA. 2009. Structurally refined β-lactones as potent inhibitors of devastating bacterial virulence factors. ChemBioChem 10:663-66
210. ZeilerE,KorotkovVS, Lorenz-BaathK,BöttcherT, Sieber SA. 2012. Development and characterization of improved β-lactone-based anti-virulence drugs targeting ClpP. Bioorg. Med. Chem. 20:583-91
211. Geiger SR, Böttcher T, Sieber SA, Cramer P. 2011. A conformational switch underlies ClpP protease function. Angew. Chem. Int. Ed. Engl. 50:5749-52
212. Gersch M, Gut F, Korotkov VS, Lehmann J, Böttcher T, et al. 2013. The mechanism of caseinolytic protease (ClpP) inhibition. Angew. Chem. Int. Ed. Engl. 52:3009-14
213. Padwal RS, Majumdar SR. 2007. Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet 369:71-77
214. Chen D-H, Naydenov A, Blankman JL, Mefford HH, Davis M, et al. 2013. Two novel mutations in ABHD12: expansion of the mutation spectrum in PHARC and assessment of their functional effects. Hum. Mutat. 34:1672-78
215. Blankman JL, Long JZ, Trauger SA, Siuzdak G, Cravatt BF. 2013. ABHD12 controls brain lysophosphatidylserine pathways that are deregulated in a murine model of the neurodegenerative disease PHARC. Proc. Natl. Acad. Sci. USA 110:1500-5
216. van der KleijD,LatzE, Brouwers JF, Kruize YC, Schmitz M, et al. 2002.A novel host-parasite lipid crosstalk. Schistosomal lyso-phosphatidylserine activates Toll-like receptor 2 and affects immune polarization. J. Biol. Chem. 277:48122-29
217. Inoue A, Ishiguro J, Kitamura H, Arima N, Okutani M, et al. 2012. TGF?shedding assay: an accurate and versatile method for detecting GPCR activation. Nat. Methods 9:1021-29
218. MiduturuCV, Deng X, Kwiatkowski N, YangW,Brault L, et al. 2011. High-throughput kinase profiling: a more efficient approach toward the discovery of new kinase inhibitors. Chem. Biol. 18:868-79
219. Deng X, Yang Q, Kwiatkowski N, Sim T, McDermott U, et al. 2011. Discovery of a benzo[e]pyrimido-[5,4-b][1,4]diazepin-6(11H)-one as a potent and selective inhibitor of big MAP kinase 1. ACSMed. Chem. Lett. 2:195-200
220. Yang Q, Lee J-D. 2011. Targeting the BMK1 MAP kinase pathway in cancer therapy. Clin. Cancer Res. 17:3527-32
221. Hayashi M, Lee J-D. 2004. Role of the BMK1/ERK5 signaling pathway: lessons from knockout mice. J. Mol. Med. 82:800-8
222. Yang Q, Liao L, Deng X, Chen R, Gray NS, et al. 2013. BMK1 is involved in the regulation of p53 through disrupting the PML-MDM2 interaction. Oncogene 32:3156-64
223. Zimprich A, Biskup S, LeitnerP,Lichtner P, FarrerM, et al. 2004. Mutations inLRRK2cause autosomaldominant parkinsonism with pleomorphic pathology. Neuron 44:601-7
224. Cookson MR. 2010. The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease. Nat. Rev. Neurosci. 11:791-97
225. Choi HG, Zhang J, Deng X, Hatcher JM, Patricelli MP, et al. 2012. Brain penetrant LRRK2 inhibitor. ACS Med. Chem. Lett. 3:658-62
226. Simon GM, Niphakis MJ, Cravatt BF. 2013. Determining target engagement in living systems. Nat. Chem. Biol. 9:200-5
227. Rosenthal PJ. 2004. Cysteine proteases of malaria parasites. Int. J. Parasitol. 34:1489-99
228. Wickham ME, Culvenor JG, Cowman AF. 2003. Selective inhibition of a two-step egress of malaria parasites from the host erythrocyte. J. Biol. Chem. 278:37658-63
229. Thompson SA, Andrews PR,Hanzlik RP. 1986. Carboxyl-modified amino acids and peptides as protease inhibitors. J. Med. Chem. 29:104-11
230. Palmer JT, Rasnick D, Klaus JL, Bromme D. 1995. Vinyl sulfones as mechanism-based cysteine protease inhibitors. J. Med. Chem. 38:3193-96
231. Weerapana E, Speers AE, Cravatt BF. 2007. Tandem orthogonal proteolysis-Activity-based protein profiling (TOP-ABPP)-A general method for mapping sites of probe modification in proteomes. Nat. Protoc. 2:1414-25
232. Kelly C, LaMont J. 2008. Clostridium difficile-more difficult than ever. N. Engl. J. Med. 359:1932-40
233. Engel M, Mazurek S, Eigenbrodt E, Welter C. 2004. Phosphoglycerate mutase-derived polypeptide inhibits glycolytic flux and induces cell growth arrest in tumor cell lines. J. Biol. Chem. 279:35803-12
234. Kondoh H, Lleonart ME, Gil J, Wang J, Degan P, et al. 2005. Glycolytic enzymes can modulate cellular life span. Cancer Res. 65:177-85
235. Evans MJ, Morris GM, Wu J, Olson AJ, Sorensen EJ, Cravatt BF. 2007. Mechanistic and structural requirements for active site labeling of phosphoglycerate mutase by spiroepoxides. Mol. Biosyst. 3:495-506
236. Hitosugi T, Zhou L, Elf S, Fan J, Kang H-B, et al. 2012. Phosphoglycerate mutase 1 coordinates glycolysis and biosynthesis to promote tumor growth. Cancer Cell 22:585-600
237. Singh A, Thornton ER, Westheimer FH. 1962. The photolysis of diazoacetylchymotrypsin. J. Biol. Chem. 237:3006-8
238. Geurink PP, Prely LM, van der Marel GA, Bischoff R, Overkleeft HS. 2012. Photoaffinity labeling in activity-based protein profiling. Top. Curr. Chem. 324:85-113
239. Sumranjit J, Chung SJ. 2013. Recent advances in target characterization and identification by photoaffinity probes. Molecules 18:10425-51
240. Lapinsky DJ. 2012. Tandem photoaffinity labeling-bioorthogonal conjugation in medicinal chemistry. Bioorg. Med. Chem. 20:6237-47
241. Martinez Molina D, Jafari R, Ignatushchenko M, Seki T, Larsson EA, et al. 2013. Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay. Science 341:84-87
242. WestGM,TangL, FitzgeraldMC.2008. Thermodynamic analysis of protein stability and ligand binding using a chemical modification-and mass spectrometry-based strategy. Anal. Chem. 80:4175-85
243. Lomenick B, Hao R, Jonai N, Chin RM, Aghajan M, et al. 2009. Target identification using drug affinity responsive target stability (DARTS). Proc. Natl. Acad. Sci. USA 106:21984-89